Philip Agop Philip

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Eileen M. O’Reilly, Do‐Youn Oh, Neesha C. Dhani et al. · JAMA Oncology · 2019 · 765 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant <i>nab</i>-paclitaxel plus gemcitabine (<i>nab</i>-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

Margaret A. Tempero, Michele Reni, Hanno Riess et al. · Journal of Clinical Oncology · 2019 · 143 citations

Medicine, Oncology, Surgery +16

SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA).

Davendra Sohal, Mai T. Duong, Syed A. Ahmad et al. · Journal of Clinical Oncology · 2020 · 115 citations

Medicine, Oncology, Perioperative Medicine +13

SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers.

Rachna T. Shroff, Katherine A. Guthrie, Aaron J. Scott et al. · Journal of Clinical Oncology · 2023 · 99 citations

Medicine, Oncology, Pharmacology +9

Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an <i>FGFR2</i> gene fusion or rearrangement.

Milind Javle, Sameek Roychowdhury, Robin Kate Kelley et al. · Journal of Clinical Oncology · 2021 · 86 citations

Medicine, Oncology, Pharmacology +17